References
- Beumer JH, Beijnen JH, Schellens JH. (2006). Mass balance studies, with a focus on anticancer drugs. Clin Pharmacokinet 45:33–58.
- Chu X, Bleasby K, Chan GH, et al. (2016). Transporters affecting biochemical test results: creatinine-drug interactions. Clin Pharmacol Ther 100:437–40.
- Dai Y, Grant S. (2010). New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 16:376–83.
- European Medicines Agency. (2012). Guideline on the Investigation of Drug Interactions (EMA/CHMP/EWP/125211/2012). Committee for Human Medicinal Products.
- FDA. (2016). Safety Testing of Drug Metabolites, Guidance for Industry. US Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Food and Drug Administration.
- Hamilton RA, Garnett WR, Kline BJ. (1981). Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408–13.
- Hong DS, Infante J, Janku F, et al. (2016). Phase I study of LY2606368, a checkpoint kinase 1 inhibitor, in patients with advanced cancer. J Clin Oncol 34:1764–71.
- Hong DS, Moore K, Patel M, et al. (2018). Evaluation of prexasertib, a checkpoint kinase 1 inhibitor, in a phase Ib study of patients with squamous cell carcinoma. Clin Cancer Res 24:3263–72.
- Hop CE, Wang Z, Chen Q, et al. (1998). Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901–3.
- King C, Diaz HB, McNeely S, et al. (2015). LY2606368 causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms. Mol Cancer Ther 14:2004–13.
- Koppen V, Jones R, Bockx M, et al. (2014). High volume injections of biological samples for sensitive metabolite profiling and quantitation. J Chromatogr A 1372c:102–9.
- Lee JM, Nair J, Zimmer A, et al. (2018). Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. Lancet Oncol 19:207–15.
- Luffer-Atlas D, Atrakchi A. (2017). A decade of drug metabolite safety testing: industry and regulatory shared learning. Expert Opin Drug Metab Toxicol 13:897–900.
- Mcneely S, Beckmann R, Bence Lin A K. (2014). CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy. Pharmacology & Therapeutics 142(1):1–10. doi:10.1016/j.pharmthera.2013.10.005
- Nijenhuis CM, Hellriegel E, Beijnen JH, et al. (2016). Pharmacokinetics and excretion of 14C-omacetaxine in patients with advanced solid tumours. Invest New Drugs 34:565–74.
- Roffey SJ, Obach RS, Gedge JI, et al. (2007). What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 39:17–43.
- Wickremsinhe ER, Hynes SM, Palmieri MD, et al. (2014). Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors. Xenobiotica 44:827–41.